We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arrowhead Pharmaceuticals Inc | NASDAQ:ARWR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.31 | 1.28% | 24.44 | 23.50 | 29.53 | 25.235 | 24.12 | 25.02 | 630,837 | 05:00:05 |
- Conference Call and Webcast Today at 4:30 p.m. EST
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended December 31, 2016. The company is hosting a conference call at 4:30 p.m. EST to discuss results.
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 59701860.
A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 404-537-3406 and enter Conference ID 59701860.
Selected Fiscal 2017 First Quarter and Recent Events
Selected Fiscal 2017 First Quarter Financial Results
ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited) Three Months Ended December 31,OPERATING SUMMARY
2016 2015 REVENUE $ 4,365,496 $ 43,750 OPERATING EXPENSES Research and development 9,527,051 10,338,833 Salaries and payroll-related costs 4,276,105 3,919,886 General and administrative expenses 1,854,174 1,951,609 Stock-based compensation 2,424,442 2,380,343 Depreciation and amortization 1,185,611 794,349 TOTAL OPERATING EXPENSES 19,267,383 19,385,020 OPERATING LOSS (14,901,887 ) (19,341,270 ) OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES 2,815,779 76,856 NET LOSS $ (12,086,108 ) $ (19,264,414 ) EARNINGS PER SHARE (BASIC AND DILUTED): $ (0.17 ) $ (0.32 ) WEIGHTED AVERAGE SHARES OUTSTANDING 71,444,600 59,548,672FINANCIAL POSITION SUMMARY
December 31, September 30,2016 2016 CASH AND CASH EQUIVALENTS 102,105,569 85,366,448 OTHER ASSETS 42,152,537 42,810,057 TOTAL ASSETS 144,258,106 128,176,505 TOTAL LIABILITIES 47,049,685 33,152,246 TOTAL STOCKHOLDERS' EQUITY 97,208,421 95,024,259 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 144,258,106 128,176,505 SHARES OUTSTANDING 74,413,040 69,746,685
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005988/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone, CFA626-304-3400ir@arrowheadpharma.comorInvestor Relations:The Trout GroupChad Rubin646-378-2947ir@arrowheadpharma.comorMedia:Russo PartnersRich Allan646-942-5588rich.allan@russopartnersllc.com
1 Year Arrowhead Pharmaceuticals Chart |
1 Month Arrowhead Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions